Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE MRA Effective against Adult RA, JIA: Chugai
November 17, 2003
-
ARCHIVE BULLETIN
November 17, 2003
-
ARCHIVE SEMIANNUAL BUSINESS RESULTS
November 17, 2003
-
ARCHIVE BUSINESS NEWS IN BRIEF
November 17, 2003
-
ARCHIVE Press Seminar
November 17, 2003
-
ARCHIVE Industry Polarization Became Marked in the Last Decade
November 17, 2003
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
November 17, 2003
-
ARCHIVE Taiyo Pharmaceutical: Sales Up 46.0%, Ordinary Profits Up 86.0%
November 17, 2003
-
ARCHIVE Chuikyo Subcommittee to Review Pricing of Insurance-covered Medical Materials
November 17, 2003
-
ARCHIVE JT: Pharma Division Sales Down 4.3%
November 17, 2003
-
ARCHIVE JCQHC Warns Against High-concentration K Preparations, 10% Xylocaine
November 17, 2003
-
ARCHIVE Kyorin: Sales Down 3.3% due to Decline in Sales of Gatiflo
November 17, 2003
-
ARCHIVE Japan's Pacemaker Market Growing Around 10% Annually
November 17, 2003
-
ARCHIVE Fujisawa's Overseas Sales Exceed 50% of Total
November 17, 2003
-
ARCHIVE BULLETIN
November 10, 2003
-
ARCHIVE Asahi Medical to Increase Production of APS Artificial Kidneys
November 10, 2003
-
ARCHIVE Kuraya Sanseido to Transfer Nagano Business to Yamahiro
November 10, 2003
-
ARCHIVE Sanki Aiming for 25% Share of Chugoku Market in 5 Years
November 10, 2003
-
ARCHIVE BUSINESS NEWS IN BRIEF
November 10, 2003
-
ARCHIVE Cataract Surgery Reduces Medical Costs: Mr Akedo of ILSAJ
November 10, 2003
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…